You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
The company recently had a second pre-submission with FDA and expects to begin a prospective trial of its test in the second half of this year.
The firm plans to conduct a prospective trial of a pan cancer assay and aims to bring another assay focused on colorectal cancer through FDA clearance.
The firm also offers an NIPT, codeveloped with Yale, that its CEO said is differentiated by its rapid time-to-result.
It will use the funds to help expand the development and commercialization of its non-invasive genetic tests for early-stage cancer detection.
Researchers showed in a new study that patterns of methylation co-occuring at different sites could help distinguish cancer DNA in the blood, and mark its original source in body.
The company was founded in mid-2014 to commercialize noninvasive prenatal testing technologies developed at Johns Hopkins and UCSD.
The company's technology will be used to analyze samples from a large cohort of Chinese volunteers to identify biomarkers for early cancer detection.
UK Royal Statistical Society is organizing a working group to develop guidelines for assessing COVID-19 tests, the Guardian reports.
The Washington Post reports that the White House chief of staff has asked the US Food and Drug Administration to justify the stricter standards it is seeking for a coronavirus vaccine.
President Donald Trump's "good genes" comment raises eugenics concerns, CNN reports.
In PLOS this week: genetic analysis of tremor condition, analysis of a West and Central African tree used in traditional medicine, and more.